In India, the human clinical trial of indigenously developed Covaxin has begun in Odisha.
Final-stage testing of experimental COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc, has begun with volunteers at various United States sites given either a real shot or a dummy without being told which is what.
It will be months before results trickle in, and there is no guarantee the vaccine will ultimately work against the scourge that has infected nearly 1.65 crore people and killed about 6,50,000 COVID-19 patients around the world.
Several other vaccines made by China and by Britain's Oxford University began smaller final-stage tests in Brazil and other hard-hit countries earlier this month.
Follow our LIVE blog for the latest updates of the novel coronavirus pandemic
In India, the human clinical trial of indigenously developed Covaxin has begun in Odisha.
Here are the latest updates on the development of COVID-19 vaccine:
> The human clinical trial of indigenously developed Covaxin, a possible vaccine against novel coronavirus, has begun at the Institute of Medical Sciences (IMS) and SUM Hospital in Bhubaneswar, Odisha. It is one of the 12 centres selected by the Indian Council of Medical Research (ICMR) for conducting phase one and two of the process.
> The world's biggest COVID-19 vaccine study got underway on July 27 with the first of 30,000 planned volunteers helping to test shots created by the US government -- one of several candidates in the final stretch of the global vaccine race.
> Five sites in India are ready for the third and final phase of human trials of the Oxford-AstraZeneca COVID-19 vaccine, said the Department of Biotechnology (DBT) Secretary Renu Swarup. This is an essential step because it is necessary to have data within the country before the vaccine is administered to Indians, Swarup told news agency PTI.
Also read | Trump to announce 'good news' on COVID-19 therapeutics in 2 weeks
> The Serum Institute of India is conducting phase III clinical trial of BCG vaccine candidate VPM1002 to evaluate its ability in reducing infection and severe disease outcomes of COVID-19 among high-risk persons of advanced age, comorbidities and high-exposure healthcare workers (HCWs), according to the Department of Biotechnology.
> German biotech BioNTech and US drugmaker Pfizer Inc have said that they would begin a pivotal global study to evaluate their lead COVID-19 vaccine candidate. If the study is successful, the companies could submit the vaccine for regulatory approval as early as October, putting them on track to supply up to 100 million doses by the end of 2020 and 1.3 billion by the end of 2021.
(With inputs from agencies)
Follow our full coverage on COVID-19 here.